INTEGRATOR Oncology Biobank

• Research type

  Research Tissue Bank

• IRAS ID

  333001

• Research summary

  INTEGRATOR Oncology Biobank

• REC name

  South West - Central Bristol Research Ethics Committee

• REC reference

  24/SW/0081

• Date of REC Opinion

  30 Jul 2024

• REC opinion

  Favourable Opinion

• Data collection arrangements

  Prospectively collected biosamples stored in INTEGRATOR will be donated from patients with a confirmed cancer diagnosis, patients who are being investigated for suspected cancer but have not yet been diagnosed and non-cancer controls (including healthy volunteers). Primarily, prospective samples of blood, tissue, urine, stool and skin-biopsies will be collected. Samples will be collected during already scheduled hospital visits concurrently to samples required for the clinical need, for example during out-patient appointments or cancer pathway investigations. This is to eliminate the need for additional hospital visits above what is required during standard of care. In some cases, access to historical samples will be requested from NHS storage. Consent for serial sampling will be sought from participants (i.e., repeated sampling at key timepoints in the patient’s cancer care). INTEGRATOR will also allow the collection and storage of samples which are not routinely collected during routine care, for example, samples required for oncology clinical trials. Clinical data will also be collected from participants, and consent will be sought to access electronic health records. Participants will be identified and approached by NHS or INTEGRATOR staff. Informed consent will be provided/recorded online, but paper-based consent provisions are available.

• Research programme

  INTEGRATOR is designed to establish a scientifically valuable, high-quality biosamples and clinical data resource for the purpose of facilitating future cancer research projects for academic, NHS and commercially led researchers/research groups. Specifically, the biobank aims to enable cancer research in priority areas including: 1) investigating the role immunology plays in cancer initiation, development, progression and response to treatment 2) how cancer, or the reoccurrence of cancer, can be detected at the earliest stage possible 3) better understanding the long-term monitoring of patients across treatment types, cancer types and cancer stages and 4) facilitating the identification, development and validation of novel cancer diagnostic technologies. Additionally, INTEGRATOR will look to adopt samples from existing collections (e.g., samples previously biobanked) and from active/closed clinical trials. Sample/data release, and the decision to adopt samples, will be strictly managed by the INTEGRATOR Management Group (consisting of the Chief Investigator, operational team members and independent researchers), who will accept project applications from researchers, reviewing them against pre-defined criteria, before releasing samples/data for use in future cancer research or accepting samples to be stored in the biobank.

• Storage license

  12217

• RTBTitle

  INTEGRATOR Oncology Biobank

• Establishment organisation

  University of Oxford - Department of Oncology

• Establishment organisation address

  Old Road Campus Research Building

  Roosevelt Drive, Headington

  Oxford

  OX3 7DQ